TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07698210: A Phase 1, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4178256 in Healthy Participants

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 88 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07698210 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07698210 Rescue Dossier →